Patents by Inventor Jau-Nan Lee

Jau-Nan Lee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220267724
    Abstract: Provided herein are isolated neural stem cells and methods of making neural stem cells from human trophoblast stem cells. The isolated neural stem cells can be immune privileged and express one or more protein(s). Also provided are methods for treatment of neurodegenerative diseases using suitable preparations comprising the isolated neural stem cells.
    Type: Application
    Filed: November 22, 2021
    Publication date: August 25, 2022
    Inventors: Jau-Nan LEE, Tony Tung-Ying LEE, Yuta LEE, Eing-Mei TSAI
  • Patent number: 11254911
    Abstract: Provided herein are isolated neural stem cells. Also provided are methods for treatment of neurodegenerative diseases using suitable preparations comprising the isolated neural stem cells.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: February 22, 2022
    Assignee: ACCELERATED BIOSCIENCES CORP.
    Inventors: Jau-Nan Lee, Tony Tung-Ying Lee, Yuta Lee, Eing-Mei Tsai
  • Publication number: 20210355436
    Abstract: Disclosed herein are precursory regulatory cytotrophoblast cells produced in vitro and compositions thereof. Disclosed herein are isolated populations of precursory regulatory cytotrophoblast cells, where the cells are produced in vitro. Disclosed herein are genetically engineered cells. Also disclosed herein are methods of treating a disorder or condition by utilizing the cells disclosed herein.
    Type: Application
    Filed: June 14, 2021
    Publication date: November 18, 2021
    Inventors: Jau-Nan LEE, Yuta LEE, Tony Tung-Yin LEE
  • Publication number: 20210330713
    Abstract: Disclosed herein are human hepatocytes for example isolated human hepatic progenitor cells, artificial tissue or organ thereof, and kits or compositions thereof. Also disclosed herein are various methods of using a human hepatocyte disclosed herein.
    Type: Application
    Filed: April 29, 2021
    Publication date: October 28, 2021
    Inventors: Jau-Nan LEE, Tony Tung-Yin LEE, Yuta LEE, Eing-Mei TSAI
  • Publication number: 20210278395
    Abstract: Disclosed herein are human trophoblast stem (hTS) cells, differentiated cells thereof, derivatives thereof such as cellular mass, and uses thereof. The isolation of hTS cells can express FGF4, FGFR-2, Oct4, Thy-1, and stage-specific embryonic antigens distributed in different compartments of the cell. The hTS cells are able to derive into specific cell phenotypes of the three primitive embryonic layers, produce chimeric reactions in mice, and retain a normal karyotype and telomere length. In the hTS cells, Oct4 and fgfr-2 expressions can be knockdown by bFGF. The hTS cells could apply to human cell differentiation and for gene and cell-based therapies.
    Type: Application
    Filed: March 15, 2021
    Publication date: September 9, 2021
    Inventors: Jau-Nan LEE, Tony Tung-Ying LEE, Yuta LEE
  • Publication number: 20210254015
    Abstract: Provided herein are methods of differentiating stem cells via modulating miR-124, and the differentiated cells thereby. Also provided herein are methods for the treatment of diseases using the differentiated cells.
    Type: Application
    Filed: April 28, 2021
    Publication date: August 19, 2021
    Inventors: Jau-Nan LEE, Tony Tung-Yin LEE, Yuta LEE
  • Patent number: 11085019
    Abstract: Disclosed herein are precursory regulatory cytotrophoblast cells produced in vitro and compositions thereof. Also disclosed herein are methods of treating a disorder or condition by utilizing the cells disclosed herein.
    Type: Grant
    Filed: May 7, 2020
    Date of Patent: August 10, 2021
    Assignee: ACCELERATED BIOSCIENCES CORP.
    Inventors: Jau-Nan Lee, Yuta Lee, Tony Tung-Yin Lee
  • Patent number: 11028366
    Abstract: Provided herein are methods of differentiating stem cells via modulating miR-124, and the differentiated cells thereby. Also provided herein are methods for the treatment of diseases using the differentiated cells.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: June 8, 2021
    Assignee: Accelerated BioSciences Corp.
    Inventors: Jau-Nan Lee, Tony Tung-Yin Lee, Yuta Lee
  • Patent number: 11026979
    Abstract: Disclosed herein are human hepatocytes for example isolated human hepatic progenitor cells, artificial tissue or organ thereof, and kits or compositions thereof. Also disclosed herein are various methods of using a human hepatocyte disclosed herein.
    Type: Grant
    Filed: July 24, 2020
    Date of Patent: June 8, 2021
    Assignee: ACCELERATED BIOSCIENCES CORP.
    Inventors: Jau-Nan Lee, Tony Tung-Yin Lee, Yuta Lee, Eing-Mei Tsai
  • Patent number: 10983111
    Abstract: Disclosed herein are human trophoblast stem (hTS) cells, differentiated cells thereof, derivatives thereof such as cellular mass, and uses thereof. The isolation of hTS cells can express FGF4, FGFR-2, Oct4, Thy-1, and stage-specific embryonic antigens distributed in different compartments of the cell. The hTS cells are able to derive into specific cell phenotypes of the three primitive embryonic layers, produce chimeric reactions in mice, and retain a normal karyotype and telomere length. In the hTS cells, Oct4 and fgfr-2 expressions can be knockdown by bFGF. The hTS cells could apply to human cell differentiation and for gene and cell-based therapies.
    Type: Grant
    Filed: July 7, 2020
    Date of Patent: April 20, 2021
    Assignee: ACCELERATED BIOSCIENCES CORP.
    Inventors: Jau-Nan Lee, Tony Tung-Ying Lee, Yuta Lee
  • Publication number: 20200354672
    Abstract: Disclosed herein are precursory regulatory cytotrophoblast cells produced in vitro and compositions thereof. Also disclosed herein are methods of treating a disorder or condition by utilizing the cells disclosed herein.
    Type: Application
    Filed: May 7, 2020
    Publication date: November 12, 2020
    Inventors: Jau-Nan LEE, Yuta LEE, Tony Tung-Yin LEE
  • Publication number: 20200345788
    Abstract: Disclosed herein are human hepatocytes for example isolated human hepatic progenitor cells, artificial tissue or organ thereof, and kits or compositions thereof. Also disclosed herein are various methods of using a human hepatocyte disclosed herein.
    Type: Application
    Filed: July 24, 2020
    Publication date: November 5, 2020
    Inventors: Jau-Nan LEE, Tony Tung-Yin LEE, Yuta LEE, Eing-Mei TSAI
  • Publication number: 20200333326
    Abstract: Disclosed herein are human trophoblast stem (hTS) cells, differentiated cells thereof, derivatives thereof such as cellular mass, and uses thereof. The isolation of hTS cells can express FGF4, FGFR-2, Oct4, Thy-1, and stage-specific embryonic antigens distributed in different compartments of the cell. The hTS cells are able to derive into specific cell phenotypes of the three primitive embryonic layers, produce chimeric reactions in mice, and retain a normal karyotype and telomere length. In the hTS cells, Oct4 and fgfr-2 expressions can be knockdown by bFGF. The hTS cells could apply to human cell differentiation and for gene and cell-based therapies.
    Type: Application
    Filed: July 7, 2020
    Publication date: October 22, 2020
    Inventors: Jau-Nan LEE, Tony Tung-Ying LEE, Yuta LEE
  • Patent number: 10765704
    Abstract: Disclosed herein are induced hepatocytes from a trophoblast stem cell, methods for inducing the cells, and compositions thereof. Also disclosed herein are methods of treating a disease or disorder (e.g., liver-associated) by utilizing an induced hepatocyte disclosed herein.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: September 8, 2020
    Assignee: ACCELERATED BIOSCIENCES CORP.
    Inventors: Jau-Nan Lee, Tony Tung-Yin Lee, Yuta Lee, Eing-Mei Tsai
  • Patent number: 10746728
    Abstract: Existence of human trophoblast stem (hTS) cells has been suspected but unproved. The isolation of hTS cells is reported in the early stage of chorionic villi by expressions of FGF4, FGFR-2, Oct4, Thy-1, and stage-specific embryonic antigens distributed in different compartments of the cell. hTS cells are able to derive into specific cell phenotypes of the three primitive embryonic layers, produce chimeric reactions in mice, and retain a normal karyotype and telomere length. In hTS cells, Oct4 and fgfr-2 expressions can be knockdown by bFGF. These facts suggest that differentiation of the hTS cells play an important role in implantation and placentation. hTS cells could apply to human cell differentiation and for gene and cell-based therapies.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: August 18, 2020
    Assignee: ACCELERATED BIOSCIENCES CORP.
    Inventors: Jau-Nan Lee, Tony Tung-Ying Lee, Yuta Lee
  • Publication number: 20190211311
    Abstract: Provided herein are methods of differentiating stem cells via modulating miR-124, and the differentiated cells thereby. Also provided herein are methods for the treatment of diseases using the differentiated cells.
    Type: Application
    Filed: March 22, 2019
    Publication date: July 11, 2019
    Inventors: Jau-Nan LEE, Tony Tung-Yin LEE, Yuta LEE
  • Patent number: 10294458
    Abstract: Provided herein are methods of differentiating stem cells via modulating miR-124, and the differentiated cells thereby. Also provided herein are methods for the treatment of diseases using the differentiated cells.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: May 21, 2019
    Assignee: ACCELERATED BIOSCIENCES CORP.
    Inventors: Jau-Nan Lee, Tony Tung-Yin Lee, Yuta Lee
  • Publication number: 20180231526
    Abstract: Existence of human trophoblast stem (hTS) cells has been suspected but unproved. The isolation of hTS cells is reported in the early stage of chorionic villi by expressions of FGF4, FGFR-2, Oct4, Thy-1, and stage-specific embryonic antigens distributed in different compartments of the cell. hTS cells are able to derive into specific cell phenotypes of the three primitive embryonic layers, produce chimeric reactions in mice, and retain a normal karyotype and telomere length. In hTS cells, Oct4 and fgfr-2 expressions can be knockdown by bFGF. These facts suggest that differentiation of the hTS cells play an important role in implantation and placentation. hTS cells could apply to human cell differentiation and for gene and cell-based therapies.
    Type: Application
    Filed: February 9, 2018
    Publication date: August 16, 2018
    Inventors: Jau-Nan LEE, Tony Tung-Ying LEE, Yuta Lee
  • Patent number: 9927426
    Abstract: Existence of human trophoblast stem (hTS) cells has been suspected but unproved. The isolation of hTS cells is reported in the early stage of chorionic villi by expressions of FGF4, FGFR-2, Oct4, Thy-1, and stage-specific embryonic antigens distributed in different compartments of the cell. hTS cells are able to derive into specific cell phenotypes of the three primitive embryonic layers, produce chimeric reactions in mice, and retain a normal karyotype and telomere length. In hTS cells, Oct4 and fgfr-2 expressions can be knockdown by bFGF. These facts suggest that differentiation of the hTS cells play an important role in implantation and placentation. hTS cells could apply to human cell differentiation and for gene and cell-based therapies. Disclosed herein are methods for treating diseases, including neurodegenerative diseases, with neural stem cells differentiated from the hTS cells such as those expressing Oct4, SSEA-1, SSEA-3, and SSEA-4.
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: March 27, 2018
    Assignee: ACCELERATED BIOSCIENCES CORP.
    Inventors: Jau-Nan Lee, Tony Tung-Ying Lee, Yuta Lee
  • Publication number: 20180000868
    Abstract: Disclosed herein are induced hepatocytes from a trophoblast stem cell, methods for inducing the cells, and compositions thereof. Also disclosed herein are methods of treating a disease or disorder (e.g., liver-associated) by utilizing an induced hepatocyte disclosed herein.
    Type: Application
    Filed: September 15, 2017
    Publication date: January 4, 2018
    Inventors: Jau-Nan LEE, Tony Tung-Yin LEE, Yuta LEE, Eing-Mei TSAI